Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...

In July, the company changed tactics on its weight loss drug, cutting the daily dose from two to one. The company is currently engaged in clinical trials on danuglipron, with results expected to ...

Ozempic, a drug developed and approved for the treatment ... While exercise is the number 1 weight loss method according to ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

It’s one of Europe’s largest ... the makers of the two most popular weight loss drugs, Ozempic and Wegovy. The company promises to offer less invasive pills, instead of injectables.